Maravai LifeSciences Sees Unusually Large Options Volume (NASDAQ:MRVI)

Key Points

• Maravai LifeSciences saw a significant increase in options trading, with investors purchasing 1,002 put options, a rise of approximately 1,791% compared to its average volume.
• The Royal Bank of Canada downgraded Maravai's target price from $7.00 to $5.00, while the stock currently has a consensus rating of "Hold" with an average price target of $5.22.
• Hedge fund activity remains strong, as various institutions have increased their holdings in Maravai LifeSciences, with notable increases from Deutsche Bank AG and 12 West Capital Management LP.

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Investors bought 1,002 put options on the company. This represents an increase of approximately 1,791% compared to the average volume of 53 put options.

Analyst Upgrades and Downgrades

Separately, Royal Bank Of Canada dropped their target price on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "outperform" rating on the stock in a report on Tuesday, August 12th. Three investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Maravai LifeSciences currently has a consensus rating of "Hold" and an average price target of $5.22.

Maravai LifeSciences Price Performance

MRVI opened at $3.14 on Thursday. The stock has a 50-day moving average price of $2.54 and a 200-day moving average price of $2.33. The company has a debt-to-equity ratio of 0.68, a current ratio of 5.16 and a quick ratio of 4.49. The firm has a market cap of $801.83 million, a PE ratio of -2.31 and a beta of 0.33. Maravai LifeSciences has a 1 year low of $1.66 and a 1 year high of $8.53.

Hedge Funds Weigh In On Maravai LifeSciences

Several large investors have recently modified their holdings of MRVI. 12 West Capital Management LP raised its position in Maravai LifeSciences by 8.0% in the 1st quarter. 12 West Capital Management LP now owns 12,521,335 shares of the company's stock worth $27,672,000 after buying an additional 930,000 shares during the last quarter. Mirabella Financial Services LLP raised its position in Maravai LifeSciences by 0.3% in the 2nd quarter. Mirabella Financial Services LLP now owns 3,750,000 shares of the company's stock worth $9,038,000 after buying an additional 10,049 shares during the last quarter. Geode Capital Management LLC raised its position in Maravai LifeSciences by 12.0% in the 2nd quarter. Geode Capital Management LLC now owns 2,984,045 shares of the company's stock worth $7,193,000 after buying an additional 319,679 shares during the last quarter. Philosophy Capital Management LLC purchased a new position in Maravai LifeSciences in the 1st quarter worth about $5,731,000. Finally, Deutsche Bank AG raised its position in Maravai LifeSciences by 67.6% in the 1st quarter. Deutsche Bank AG now owns 2,072,239 shares of the company's stock worth $4,580,000 after buying an additional 835,600 shares during the last quarter. Hedge funds and other institutional investors own 50.25% of the company's stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.